Aripiprazol: farmacología, eficacia clínica, seguridad y tolerabilidad en el adulto.

摘要: Aripiprazole is the first representative of a group antipsychotic with partial agonist D2 dopamine receptors, in so-called third-generation antipsychotics, also known as agonists, stabilizers or “modulators dopamine-serotonin system”. Clinical trials have shown that aripiprazole effective adults for treatment schizophrenia, schizoaffective disorder, manic episodes and prevention these long-term, associated antidepressants melancholia does not respond to common antidepressant. The efficacy other disorders promising but are still required carry out new well-designed clinical trials. characterized by excellent tolerance safety profile, low incidence sedation extrapyramidal side effects, poor weight gain, lack metabolic good profile on cognitive functions increase prolactin levels prolongs QTc interval. To achieve this tolerability important become familiar its dosage strategy change from one prevent akathisia, activation syndrome.